Why is ACRS down?
Down 8% on Nov 16, a down day for the market: the S&P 500 fell 2%, 76% of stocks fell, and biotech stocks a median 3%.
“Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD).”
−2Growth
Why ACRS still beats the market over three years
Up 266% over the three years to Nov 20 while the S&P 500 rose 58%; down 8% on Nov 16.
1 reason, from its filings, with the timeline and its peers, for Pro members.